Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SurVaxM is my bet. FDA Fast tracked.
https://clinicaltrials.gov/study/NCT05163080?term=NCT05163080&rank=1
https://www.mimivax.com/about/#leadership
Also seems pretty obvious that LP dragged the process out for years until MHRA cut its umbilical cord to the EMA.
>>There is an obvious reason for not applying.
What I wouldn't give to see a thorough analysis by a bean counter.
>>The Company must have spent close to half a billion dollars in the phase 3 trial while most of the trial sites are in the US; how could they NOT apply for FDA approval??
If there were actually any new shareholders here you'd think they'd at least chime in before the disciples capture them. Hmm
>>Marksans Pharma Ltd shares gained nearly 3% on Tuesday after the company announced the UK health regulator’s approval to market an oral solution for controlling certain seizures in treating epilepsy.
>>The pharmaceutical company has stated that the product will be manufactured at the company’s manufacturing facility located in the UK.
>>Last month, the Massachusetts Institute of Technology (MIT) acquired a 1.45% stake, equivalent to 66 lakh equity shares of Marksans Pharma at ?158 per piece through a block deal in April.
Busy Indian company.
https://www.marksanspharma.com/press-release.html
Was really hoping someone would come through by now:
-Show us just one other active Plll public biotech whose CEO is also a permanent CFO and Chairman.
-Show us just one other public biotech whose CEO owns a private CDMO. If you can do that then show one where it was inserted into operations and relied upon.
-Show us one other public biotech where top management have allowed their own employee contracts to expire years ago.
-Show us one other public biotech where the CEO hasn't been seen on a stage in five years.
Now, once you've done that, show us just one public biotech anywhere in western society which possesses all four governance issues.
Good luck to you. Serious replies only please.
The company doesn't need to do those things just as long as they're being done in the fertile minds of many on these message boards.
>>The funding has been split between research groups from Cambridge, Australia and California which are working on targeted immunotherapy techniques to treat glioblastoma.
https://www.bbc.com/news/articles/c0kkzke4knzo.amp
AKA the Plll's Inclusion criteria.
>>So out of a 1000+ clinical trial patients it is relatively easy to select candidates who you could predict would stand a better chance of survival than the majority.
My primary concern is with governance of a public company not the therapy. I am skeptical of the Plll but the therapy may very well have possibilities down the line. Those possibilities all should've been explored years ago but for this management crew.
Symbol change to BORG.
Says it all. Can't make it up.
>>There is no hiring on the commercial front so they must have someone waiting in the wings to take GBM on as soon as we get approved. On the other hand, Advent has been on a hiring spree for many months.
Like a new CEO maybe.
>>real news that can affect time to revenue and revenue potential.
I feel this post warrants attention:
Also hard to imagine someone holding 11,000 shares could or would run up millions of dollars in attorney fees. Then just to have "management" make another run for the options with no statement by the plaintiff or demand for concessions. Doesn't add up.
>>Plaintiff will ask the Court to approve an award of millions of dollars of fees to the Plaintiff’s attorneys payable by the Company.
This part is right but the rest completely delusional.
>>There will be no buyout
-To maintain control
-Leverage for borrowing
-Leverage for shorting
-maybe because the true value is so little that she needs all the shares she can get.
>>Why would she even bother with her options?
DrugRunner, you're a drug runner. Enough said.
Just reflecting I've noticed this new generation doesn't care much for "Experience". In fact, it's the reverse split of a belief system where bad behavior is completely tolerable.
Said the same in 2014.
I have that!!! Think it's worth something.
....It seems those considered superior primates shower down on their underlings.
Do not bring up "unethical".
What the heck ever happened to Mercidenzel or whatever it was called?
I'm doing an article in Nature on Naked Showering.
I suspect JJ was fired for doing such a bad job. Enter the new director.
A glimmer of hope coming from QL. It's a beautiful thing.
Absolutely. No normal biotech would say "Oh, and by the way, they called us again to say everything is order." LOL
Yup. Also hard to imagine someone holding 11,000 shares could or would run up millions of dollars in attorney fees. Then just to have "management" make another run for the options with no statement by the plaintiff or demand for concessions. Doesn't add up.
>>Plaintiff will ask the Court to approve an award of millions of dollars of fees to the Plaintiff’s attorneys payable by the Company.
The other day a friend told me she was channel surfing and saw Les, but he got interrupted by a Chuck E. Cheese commercial.
Interesting move. They do have the ASCO experience under their belt.
>>bid to run the concessions for coffee kiosks
Costco does have those rostiserie chickens. Hmm??
Welcome to the 0.00089%ers club!
I predict the ASM will go off with barely a ripple. Market will open that Monday perhaps adjusting for the re-true-up award.
Well, at least they'll have their reconstituted options. Eye rolls.
It should be obvious Les' appearance all but assured there is no buyout. So given the Advent arrangement, the tiny regulator, the pinched for cash UK health system, along with the governance history, anyone willing to even fund this company likely thinks the true market cap is probably around $200M.
Is it Friday yet?
Still waiting for serious replies. Danish?
>>The challenge, DanishDancer or any other disciple, should you accept it:
-Show us just one other active Plll public biotech whose CEO is also a permanent CFO and Chairman.
-Show us just one other public biotech whose CEO owns a private CDMO. If you can do that then show one where it was inserted into operations and relied upon.
-Show us one other public biotech where top management have allowed their own employee contracts to expire years ago.
-Show us one other public biotech where the CEO hasn't been seen on a stage in five years.
Now, once you've done that, show us just one public biotech anywhere in western society which possesses all four governance issues.
Good luck to you. Serious replies only please.
Les said the FALL! Get it through your thick skulls!
Oh, he also mentioned he had 50,000 retail shareholders for some reason. Lol.
Nemesis, those two trial participation comments-questions from yesterday are worthy and deserve your response.